


 SFU

 Weill Cornell  
 Medicine

 BRITISH COLUMBIA  
 CENTRE for EXCELLENCE  
 in HIV/AIDS


# A case of super-infection with two highly divergent HIV-1 strains: implications for the latent reservoir

**Natalie N. Kinloch**<sup>1,2</sup>, Winnie Dong<sup>2</sup>, Pragma Khadka<sup>3</sup>, Andrew Wilson<sup>4</sup>, Erika Benko<sup>5</sup>, Mario Ostrowski<sup>6</sup>, Jeffrey B Joy<sup>2,7</sup>,  
 Rebecca M. Lynch<sup>4</sup>, Chanson J. Brumme<sup>2,7</sup>, Colin Kovacs<sup>5</sup>, R. Brad Jones<sup>3,4</sup>, Zabrina L. Brumme<sup>1,2</sup>, Guinevere Q. Lee<sup>3</sup>

<sup>1</sup>Faculty of Health Sciences, Simon Fraser University, Burnaby BC; <sup>2</sup>BC Centre for Excellence in HIV/AIDS, Vancouver BC;

<sup>3</sup>Division of Infectious Disease, Weill Cornell Medical College, New York, USA; <sup>4</sup>School of Medicine and Health Sciences, George Washington University, Washington DC, USA; <sup>5</sup>Maple Leaf Clinic, Toronto, ON; <sup>6</sup>Department of Immunology, University of Toronto, Toronto, ON;

<sup>7</sup>Faculty of Medicine, University of British Columbia, Vancouver BC

**Conflict of Interest Disclosure:**  
 none to declare


Contact: [nkinloch@sfu.ca](mailto:nkinloch@sfu.ca)

## BACKGROUND and OBJECTIVE:


The dynamics of HIV co-/super-infections with multiple subtypes are poorly understood, particularly as these relate to reservoir seeding and persistence. We describe a unique case of initial subtype B infection followed by super-infection by a unique recombinant form (URF) in a participant of an HIV cohort study in Canada.

## STUDY PARTICIPANT CLINICAL AND SAMPLING HISTORY:

OM5346 is a 51-year old male of African decent living in Toronto, ON. Diagnosed with HIV in June 2010, he initiated ART in May 2012 and clinical HIV drug resistance genotyping identified a subtype B infection. He maintained viral suppression until May 2018 (aside from a small viral blip in August 2013) when he underwent Analytical Treatment Interruption (ATI). Viral rebound occurred ~2 weeks after treatment cessation and ART was re-initiated (suppression achieved July 2018). Sample timepoints, type and sequences recovered are indicated below.



2012 drug resistance testing genotype




Subtype B

100

Unique Recombinant Form (URF)

0.008




## RESULTS: OM5346 is infected with both subtype B and a Unique Recombinant Form (URF)

OM5346 was originally **clinically genotyped (2012)** as infected with subtype B. However, additional retrospective single-genome *pol* and *gp120* amplification and sequencing from **2010** and **2012** pre-ART plasma samples, as well as full genome amplification and sequencing from the **proviral (2017, 2019)** and **replication competent (2017)** reservoir revealed OM5346 to be super-infected with both a subtype B and a non-B strain.

**Figure 1 (left): Maximum likelihood phylogenetic tree of *pol* sequences from OM5346.** Two distinct clades are observed: one subtype B (top) and the other non-B (bottom). *Pol* was excised from full genome sequences when present using GeneCutter (HIV LANL). Scale= nucleotide substitutions/site. Bootstrap values are indicated below nodes. Notably, both viral strains (as **proviruses** and **replication competent outgrowth viruses**) were represented in the reservoir.

*gp120* phylogeny (not shown) exhibited a similar structure. No within-host recombinants (between B and non-B strains) were observed. RIP 3.0 analysis of full genome sequences of the non-B strain revealed it to be a previously un-described Unique Recombinant Form (URF) comprised of subtype **A1**, **G** and **CRF02\_AG**

**Figure 2 (below): Schematic of Unique Recombinant Form (URF) infecting OM5346.** Breakpoints are approximate.



- 2010 pre-ART plasma
- 2012 pre-ART plasma
- 2012 drug resistance testing genotype
- 2017/2019 proviral reservoir
- 2017 reservoir replication competent reservoir

# Unique Recombinant Form (URF) *pol*



# RESULTS 2: Super-infection occurred between 2010-2012

Figure 3 (left): OM5346 maximum likelihood *pol* phylogenies, separated by subtype.

All Pre-ART sequences sampled from plasma in 2010 are subtype B (red sequences only observed in subtype B tree, not in URF tree), while those sampled from 2012 were both subtype B and URF (blue sequences are in both subtype B and URF trees), though subtype B sequences were relatively infrequent at this timepoint.

This indicates that OM5346 was initially infected with subtype B in 2010 and subsequently super-infected with the URF, which then dominated untreated infection before ART was initiated in May 2012.

# RESULTS 3: OM5346 reservoir subtype distribution resembles that of plasma RNA immediately pre-ART (2012)




Figure 4 (above): Subtype distribution of HIV sequences in 2010 and 2012 plasma RNA and 2017/2019 reservoir. Subtype B and URF sequences were observed at similar frequencies in 2012 plasma HIV RNA and viral reservoir sampled in 2017/2019, where the URF dominated both time points.

## **SUMMARY:**

Retrospective pre-ART plasma sampling identified a case of super-infection with highly divergent HIV strains in an individual recruited to a HIV cohort Study in Toronto, Ontario.

Initial infection occurred with a subtype B strain in 2010. Later, super-infection occurred with a previously un-described unique recombinant form (URF), comprising subtype G, A1 and CRF02\_AG. By the time ART was initiated in 2012, the URF had become the dominant circulating strain.

Subtype distribution in the HIV reservoir measured 5 and 7 years following ART initiation reflected pre-ART subtype distribution, with replication competent viruses of both infecting strains recovered by QVOA.

No within-host recombinants were observed.

## **CONCLUSIONS:**

Super-/co-infection with multiple HIV strains yields a genetically complex, replication competent HIV reservoir comprising highly distinct HIV quasispecies.

Treatment interruption carries the risk of *de novo* within-host recombination events.

Such cases of extreme within-host HIV diversity may complicate HIV remission strategies.

Future studies should be conducted to investigate reservoir size and composition in additional individuals infected with multiple HIV subtypes.

**We thank the study participant, without whom this research would not be possible.**

